Lipids & metabolic liver disease
Objective Measures of Cardiometabolic Risk and Advanced Fibrosis Risk Progression in Primary Care Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Authors' conclusion
Nearly 1 in 5 primary care patients with MASLD transitioned to a high-risk FIB-4 score during 3.6 years of follow-up, and uncontrolled blood pressure and reduced kidney function were associated with an increased hazard of a FIB-4 at high-risk for advanced fibrosis.
Study context
- Population
- Primary care patients with MASLD and low- or indeterminate-risk FIB-4 scores, 2012–2021
- Participants
- 1,347 patients
- Exposure
- Cardiometabolic risk measures categorized by primary care therapy-intensification thresholds
- Outcome
- Time to a high-risk FIB-4 (≥2.67)
Methodological detailsprimary care
- Primary care
Main finding
As reported in the abstract
High-risk FIB-4 · mean follow-up 3.6 years (SD 2.7)
Subsequent FIB-4 > 2.67
258
19%
Mean systolic blood pressure ≥ 150 mm Hg, fully adjusted
1.57
95% CI 1.02–2.41
Glomerular filtration rate ≤ 59 ml/min, fully adjusted HR
2.78
95% CI 2.17–3.58
Statin prescription, fully adjusted HR
0.51
95% CI 0.39–0.66
Observational data: associations, not effects.
Original publication
Objective Measures of Cardiometabolic Risk and Advanced Fibrosis Risk Progression in Primary Care Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Endocr Pract. Published 8 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →